The Accomplishments of Clay Siegal in the Cancer Treatment Field

Seattle Genetics is a globally recognized biotechnology research firm that has focused on developing targeted cancer cures. It was created in 1998, and its headquarters are located in Washington. The company has more than 900 employees who have been working to ensure its growth in the international markets. Seattle Genetics has developed several drugs that have had a positive impact on the pharmaceuticals sector. The firm is currently focused on conducting both research and marketing of its products. To achieve this, it has invested a lot of resources, and it plans to employ about 200 more individuals in 2017. The primary drug that Seattle Genetics sells is known as Adcetris. It is a cure for Hodgkin lymphoma, which is a life threating cancer that starts by infecting the lymph and spreads to other parts of the body. The drug is now in its last stage of development and testing.

 

The research firm’s CEO and chairman is Dr. Clay Siegall. He is a renowned expert in biotechnology and genetics and has a three decade’s experience in both fields. Siegall is striving to ensure that Seattle Genetics grows into one of the pharmaceuticals industry’s most significant companies. He is determined to build it into a global drug manufacturer that markets its products. A few years ago, the enterprise had sold its trading rights to a global company that is known as Takeda Oncology. The firm currently understands the international pharmaceuticals market, and it has established offices in Switzerland to run its global businesses.

 

Siegall’s outstanding business management expertise has enabled the firm to grow at a rapid rate. The company has been making profits from selling its drugs and generated $418 million in 2016. This amount was 46 percent higher than what it made in 2014. The value of the company’s stocks has tripled in the past three years from $20 to $66 per share. Seattle Genetics is currently focused on developing antibody-drug conjugates (ADC) and has dedicated over $376 million to the project. Many physicians recommend the use of ADCs since they do not damage the healthy body cells.

 

Seattle Genetics has secured an FDA license for the manufacture and commercialization of Adcetris. According to Siegall, the company will raise over $1 billion from selling the drug. Patients who used the drug can spend from $230,000 to $330,000 per annum. Clay Siegall has developed several new cancer cures, and he has 15 patents.

Study Shows New Treatment for Multiple Sclerosis

The National Institute of Health (NIH) is a medical research agency that works under the United States Department of Health. The agency recently ran medical trials seeking to test for treat Multiple Sclerosis. MS is an auto-immune affliction in which the central nervous system is attacked by the immune system. There is no known cure at the moment, and that is why the NIH has its sights set on helping those affected by this disease.

 

This experimental treatment is aiming to suppress MS by removing the disease-causing cells and letting the immune system reset itself. Before the procedure, doctors collect the patient’s stem cells and proceed to destroy their immune system through chemotherapy. Afterward, the stem cells are re-introduced into the patient’s immune system, and they immediately start the process of restoring it anew. The treatment is referred to as high dose immuno-suppressive therapy HDIT or hematopoietic cell transplant HCT.

 

Five years after receiving the HDIC/HCT treatment, 69% of the patients have not experienced any symptoms of relapse of their Multiple Sclerosis. There weren’t any cases of progressing disability or new brain lesions either. The participants were chosen from a group of patients aged 26-52 with relapsing MS. They did not take any other form of treatment aside from HDIT/HCT thus proving the success of the clinical trial.

 

About Dr. Shiva Gopal Vasishta

Dr. Shiva Gopal Vasishta is a neurologist who is applying some of the same aspects to help his patients. Shiva is a New Jersey native with 40 years of medical experience. After his graduation in 1979, Dr. Gopal did his residency in Boston city hospital. Specializing in neurology and psychiatry, he works with the Kennedy Health System and the Eastern NeuroDiagnostic Associates.

 

As a board certified neurologist, Dr. Gopal is at the forefront of his field. Vasishta’s private practice in Vorhees, New Jersey is always abuzz with activity with new patients seeking his expertise in the field. As one of only 38 neurologists in the region, he is uniquely placed to help patients with certain ailments. As an added edge, Dr. Gopal is fluent in both English and Spanish.

 

The National Institute of Health (NIH) is a medical research agency that works under the United States Department of Health. The agency recently ran medical trials seeking to test for treat Multiple Sclerosis. MS is an auto-immune affliction in which the central nervous system is attacked by the immune system. There is no known cure at the moment, and that is why the NIH has its sights set on helping those affected by this disease.

 

This experimental treatment is aiming to suppress MS by removing the disease-causing cells and letting the immune system reset itself. Before the procedure, doctors collect the patient’s stem cells and proceed to destroy their immune system through chemotherapy. Afterward, the stem cells are re-introduced into the patient’s immune system, and they immediately start the process of restoring it anew. The treatment is referred to as high dose immuno-suppressive therapy HDIT or hematopoietic cell transplant HCT.

 

Five years after receiving the HDIC/HCT treatment, 69% of the patients have not experienced any symptoms of relapse of their Multiple Sclerosis. There weren’t any cases of progressing disability or new brain lesions either. The participants were chosen from a group of patients aged 26-52 with relapsing MS. They did not take any other form of treatment aside from HDIT/HCT thus proving the success of the clinical trial.

 

About Dr. Shiva Gopal Vasishta

Dr. Shiva Gopal Vasishta is a neurologist who is applying some of the same aspects to help his patients. Shiva is a New Jersey native with 40 years of medical experience. After his graduation in 1979, Dr. Gopal did his residency in Boston city hospital. Specializing in neurology and psychiatry, he works with the Kennedy Health System and the Eastern NeuroDiagnostic Associates.

 

As a board certified neurologist, Dr. Gopal is at the forefront of his field. Vasishta’s private practice in Vorhees, New Jersey is always abuzz with activity with new patients seeking his expertise in the field. As one of only 38 neurologists in the region, he is uniquely placed to help patients with certain ailments. As an added edge, Dr. Gopal is fluent in both English and Spanish.